Handa Pharmaceuticals, Inc.

6620

TW0006620008

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
130.5 ^TWD	-2.25%		+9.21%	-28.88%

Apr. 02	Handa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Handa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Handa Pharmaceuticals, Inc.(TPEX:6620) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Handa Pharmaceuticals, Inc.

Handa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
Handa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Dec. 26	CI
Handa Pharmaceuticals, Inc.(TPEX:6620) added to S&P Global BMI Index	23-09-18	CI
Handa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI
Handa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-20	CI
Handa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-15	CI
Handa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-27	CI
Handa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-12	CI
Handa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-28	CI
Handa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-11	CI
Handa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-28	CI
Handa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-13	CI

Chart Handa Pharmaceuticals, Inc.

Duration

Period

More charts

Handa Pharmaceuticals Inc is a Taiwan-based pharmaceutical company focused on the development of niche drug. The Company integrates its own pharmaceutical development platform with patent analysis, medicine and pharmaceuticals regulatory, and market planning to focus on the development of high barrier and patentable niche products, including 505(b)2 new drug development and high barrier/patentable generics development. Its products include marketed products, such as Quetiapine XR Tablets for treatment of sleep disorder diseases, Lamotrigine XR Tablets for treatment of anti-epileptic diseases and Dexlansoprazole DR Capsules for treatment of erosive reflux esophagitis and non-erosive gastroesophageal reflux diseases. The Company's products are mainly sold to the United States, Canada and India.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for Handa Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

130.5 TWD

Average target price

200 TWD

Spread / Average Target

+53.26%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HANDA PHARMACEUTICALS, INC.	-28.88%	564M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.77%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+12.37%	13.64B
ZYDUS LIFESCIENCES LIMITED	+39.97%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B

Generic Pharmaceuticals